A Clinical Study Evaluating Licaminlimab for Dry Eye Disease
A Phase 2b/3, Double-masked, Randomized, Vehicle-controlled, Multicenter Study Evaluating Licaminlimab in Dry Eye Disease Patients With a Specific TNFR1 Genotype
Oculis
160 participants
Apr 16, 2026
INTERVENTIONAL
Conditions
Summary
The primary objective of this study is to evaluate the efficacy and safety of the topical ophthalmic administration of licaminlimab as compared to vehicle in participants with Dry Eye Disease and a specific genotype.
Eligibility
Inclusion Criteria3
- Physician diagnosis of Dry Eye Disease in the past 6 months
- Use of over-the-counter tears
- Must agree to genotype testing
Exclusion Criteria1
- \- Have a history or presence of any disorder or condition that may, in the opinion of the Investigator, likely interfere with the interpretation of the study results or participant safety.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Artificial tear eye drop run-in three times daily (TID) for approximately 14 days.
Licaminlimab eye drops three times daily (TID) for 29 days.
Inert ophthalmic solution vehicle of licaminlimab, three times daily (TID) for 29 days.
Locations(10)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07548632